It is estimated that more than 2.5 million individuals worldwide have multiple sclerosis (MS). MS is an 
diagnosis, but are not MS-specific [2, 6] . 
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Recently the portfolio of approved MS treatments was enriched by more options that encircle two major 
67
Teriflunomide is an oral medication that interferes with the fast expansion of recently activated 68 lymphocytes, preserving the basal proliferation of memory cells. It has a moderate efficacy, similar to 69 interferons, but some safety concerns, including teratogenic potential [10] . Dymethylfumarate is an oral 70 treatment with a putative dual mechanism of action, including immunosuppression and neuroprotection.
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In clinical trials it demonstrated a good efficacy in controlling the disease but concerns regarding its long-72 term safety, particularly the profound lymphopenia and the risk of a serious opportunistic CNS infection,
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progressive multifocal leukoencephalopathy (PML), might limit its use [11] . Fingolimod, a functional 74 antagonist of S1P receptors that blocks lymphocyte egress from lymph nodes [12] , has also a good 75 efficacy but similar concerns over lymphopenia and PML [8] . Natalizumab is a highly efficacious 76 monoclonal antibody that blocks lymphocyte entry into the CNS; however, it is associated with a high risk 77 of PML in patients which have antibodies against the causing organism, JC virus, which almost limits its 78 use to seronegative patients representing less than half of MS patients [13] . 
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Although data are still preliminary, ocrelizumab may increase the risk of serious infections, including PML,
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which might limit its use. Targeting both B and T cells, alemtuzumab is a monoclonal antibody that 86 induces a severe depletion of circulating lymphocytes and is said to "reset" the immune system [16] .
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Upon immune reconstitution, alemtuzumab-treated patients are able to stay disease free for periods of up 
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As can be gleaned from the above, MS treatments are in an exciting era, with several new options being 93 approved, many more in the pipeline, and new drug targets and modes of action being available. More 94 importantly, some treatments have been shown to allow a reset of the immune system, which might make 95 a cure even more reachable than before. However, we weren't able, so far, of breaking the close ties 96 between efficacy and risk. These severely limit the use of more efficacious medications in all patients and 97 the extension of their benefits to all patients. Thus, the finding of a highly efficacious and safe therapeutic 98 is still an unmet medical need. This paves the way for nanotechnology-based approaches.
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Nanoengineered systems for MS therapeutics 101
The use of nanotechnology and in particular of nanoparticles has been actively investigated for the 
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In MS, the use of nanoparticles has been investigated within two major applications: 1) as drug delivery 
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Importantly, nanoparticles have also been explored as vectors for antigen-specific immunomodulation.
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The delivery of autoantigens related with the autoimmune response in MS is expected to allow the 
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The results achieved so far using nanoparticles to induce immunotolerance are promising and should 
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The improved antigen immunogenicity using microneedle devices is considered to be related to the 175 delivery of antigens at the epidermal and intradermal layer of the skin. The skin is highly rich in 
